logo
Plus   Neg
Share
Email

Bayer To Report Phase III EINSTEIN-PE Results In Late-BreakingTrials At ACC 2012

Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the Phase III EINSTEIN-PE study, with nearly 5,000 patients, would be presented in the Late-Breaking Clinical Trials Session on Monday, March 26th, 2012, 08:00 - 09:30am CDT, at the American College of Cardiology's 61st Annual Scientific Sessions or ACC in Chicago, USA, by lead investigator Harry Buller, MD, Academic Medical Center, Amsterdam, the Netherlands.

The EINSTEIN-PE study compared an oral single-drug approach with rivaroxaban, intensified initial treatment with rivaroxaban 15 mg twice daily for three weeks followed by 20 mg once daily, with the current standard of care of initial subcutaneous enoxaparin followed by a VKA in patients with acute symptomatic pulmonary embolism or PE with or without symptomatic deep vein thrombosis or DVT.

This multinational, randomized, event-driven trial with blinded outcome assessment was sponsored by Bayer HealthCare and Janssen Research & Development, LLC.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Tens of thousands of casino workers in Las Vegas voted Tuesday to authorize a city-wide strike anytime after June 1 if labor contract agreements are not reached before they expire at the end of May. This would be the first strike in more than three decades in Las Vegas and could cripple the city's famed hospitality industry. Ten former and current employees of McDonald's Corp. have filed sexual harassment complaints with the federal government against the fast food giant. The women filed the complaints with the U.S. Equal Employment Opportunity Commission or EEOC and are receiving support from Fight for $15, which is organizing the effort. The TIME's UP Legal Defense Fund is covering legal fees for the women. A bill rolling back financial regulations implemented following the 2008 financial crisis is headed to President Donald Trump's desk for his signature after being approved by the House on Tuesday. The House voted 258 to 159 in favor of the Economic Growth, Regulatory Relief, and Consumer Protection...
Follow RTT